Safety Of Luitpold’s Intravenous Iron Product Injectafer Set For Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional data submitted and sponsor predicts FDA decision in first quarter.
You may also be interested in...
AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.
AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.
Advanced Magnetics Sees Ferumoxytol NDA For Chronic Kidney Disease By Year End
The developer of nanotechnology-based therapeutics will require a 70-person sales force to promote ferumoxytol in the U.S., firm’s CEO tells “The Pink Sheet” DAILY.